Epileptic Seizures Treatment Market Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Epileptic Seizures Treatment Market

Epilepsy is a brain condition that affects people of all ages and is a chronic non-communicable disease. Epilepsy can strike at any age, however it most commonly strikes children or persons over the age of 60. Seizures have varying effects on people depending on which section of the brain is engaged. Uncontrollable jerking and shaking, known as a 'fit,' loss of awareness and staring blankly into space, stiffness, peculiar feelings in the stomach, unusual smell or taste, tingling sensation in the arms or legs, and collapse are all possible epilepsy symptoms. Anti-epileptic medication therapy, brain surgery, vagus nerve stimulation, deep brain stimulation, and the ketogenic diet are the most prevalent treatments for epileptic seizures.

The need for epilepsy therapy remained unchanged during the COVID-19 pandemic, despite the fact that epilepsy and COVID-19 infection do not appear to be linked. There is no concrete proof that a coronavirus infection causes epilepsy, according to the International League Against Epilepsy. Infected people who are prone to epilepsy may experience breakthrough episodes, much as most illnesses can induce high fevers, breathing difficulties, and other issues with regular functioning. Although medication supply disruptions have had a little detrimental influence on the epileptic seizures treatment industry.

According to Coherent Market Insights, The Epileptic Seizures Treatment Market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).

Over the projected period, rising clinical trials for novel drugs to treat epileptic seizures are likely to propel the epileptic seizures treatment market forward. For example, Xenon Pharmaceuticals Inc., in conjunction with NCGS, Inc., began a clinical trial on the medication XEN1101 for the treatment of focal epilepsy in January 2019. The goal of the study is to assess the clinical effectiveness, safety, and tolerability of XEN1101 when used as an adjunctive therapy in adult patients with focal epilepsy aged 18 to 75 years. In this study, 300 patients are randomised to receive either XEN1101 or placebo capsules. This clinical trial is now in phase 2 and will be completed in June 2022.

Furthermore, the worldwide epileptic seizures treatment market is predicted to develop due to an increase in pharmacological approvals and launches for the treatment of epileptic seizures. For example, Eisai Co., Ltd. recently received a New Drug Approval from the China National Medical Products Administration (NMPA) for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (perampanel) for use in the adjunctive treatment of partial onset seizures (with or without secondary generalised seizures) in epilepsy patients 12 years of age and older. As a result, such approvals are projected to have a beneficial influence on the growth of the worldwide epileptic seizures therapy market.

Anti-epileptic medicines can cause minor or severe neurological side effects, but they can also be lethal. Each drug has its own set of side effects and hazards. Antiepileptic medications, in general, have the potential to trigger an allergic response. These medicines enhance the likelihood of diseases including violent behaviour and depression in an indirect way. Anti-epileptic medicines can damage the baby in pregnant women. The Journal of Family Practice lists the following anti-epileptic medication negative effects: Phenytoin produces the Fetal Hydantoin Syndrome (FHS), which is characterised by varying degrees of hypoplasia and ossification of the distal phalanges, as well as craniofacial abnormalities.

Anticonvulsants, especially hydantoins and barbiturates, have also been linked to hemorrhagic disorders in babies. As a result, the market for epileptic seizures therapy is projected to be hampered by such severe side effects throughout the forecast period.

Major companies Covered are- Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.